China Targeted Therapy Market Size & Growth Rate
According to 6Wresearch internal database and industry insights, the China Targeted Therapy Market was valued at USD 2.26 billion in 2025 and is projected to reach USD 3.54 billion by 2032, growing at a CAGR of approximately 6.6% during 2026–2032.
China Targeted Therapy Market Highlights
| Report Metric | Details |
| Report Name | China Targeted Therapy Market |
| Market Size 2025 | USD 2.26 billion |
| Market Size 2032 | USD 3.54 billion |
| Absolute Growth 2025–2032 | USD 1.28 billion |
| CAGR 2026–2032 | 6.6% |
| Peak Annual Growth | 8.5% in 2029 |
| Forecast Period | 2026–2032 |
| Historical Data | 2022–2025 |
| Base Year | 2025 |
| Leading Therapy Type, 2025 | Biologic Therapies (35% share) |
| Leading Disease Indication, 2025 | Oncology (40% share) |
| Leading Delivery Mode, 2025 | Injection/IV (52% share) |
| Leading End User, 2025 | Hospitals (49% share) |
| Fastest-Growing Therapy Type | RNA-Based Therapies (8.3% CAGR) |
| Fastest-Growing Disease Indication | Genetic Disorders (8.2% CAGR) |
| Fastest-Growing Delivery Mode | Nucleic Acid Delivery (8.8% CAGR) |
| Fastest-Growing End User | Specialty Clinics (8.7% CAGR) |
| Growing Sector | Oncology |
| Key End Users | Hospitals, Specialty Clinics, Research Hospitals |
China Targeted Therapy Market Year-wise Growth Rate and Key Drivers (2022–2032)
This graph illustrates the annual growth rates of the market from 2022 to 2032, highlighting a steady upward trajectory and projected market expansion over the forecast period.
Annual growth estimates for each year appear below with the principal reason behind them, explaining the shifts that set the pace of the market.
| Year | Estimated Annual Growth (%) | Market Rationale |
| 2022 | 8.0 | The market experienced strong growth due to high patient demand for advanced cancer treatments. |
| 2023 | 4.5 | Growth slowed as hospitals adjusted to new treatment protocols and patient access issues arose. |
| 2024 | 5.7 | Increased clinical trials for targeted therapies boosted growth as more options became available. |
| 2025 | 5.2 | A slight slowdown occurred as hospitals faced challenges in integrating new therapies into existing systems. |
| 2026 | 8.4 | Demand accelerated again as new therapies gained regulatory approval and market acceptance. |
| 2027 | 6.5 | Growth slowed as the market began to stabilise following rapid expansion in previous years. |
| 2028 | 5.6 | A continued slowdown was noted as the market adjusted to a more mature phase of development. |
| 2029 | 8.5 | The market peaked with renewed interest in targeted therapies driven by rising cancer rates. |
| 2030 | 5.7 | Growth slowed as the market began to normalise after the peak in 2029. |
| 2031 | 6.7 | A rise in growth was noted as new therapies entered the market and expanded treatment options. |
| 2032 | 5.0 | Growth slowed again as the market stabilised, reflecting a more mature phase of development. |
Note: Market size estimations and growth projections presented in this report are based on 6Wresearch's proprietary forecasting methodology, utilizing the latest available industry data, government publications, and primary research inputs.
China Targeted Therapy Market Synopsis
Targeted Therapy in China includes advanced cancer treatments that specifically target cancer cells while leaving normal cells unharmed. Developed through biotechnological methods, these therapies are mainly utilised in oncology. The China Targeted Therapy Market is growing due to increasing cancer rates, with targeted therapies representing 30% of oncology treatments in hospitals. Approximately 50,000 patients receive targeted therapy in major hospitals each year. Government initiatives are enhancing access to these therapies, further boosting demand.
Market Dynamics Impact Analysis (2026–2032)
| Factor | Type | Impact | Primary Segment Affected |
| Increasing cancer rates in urban areas drive demand for targeted therapies. | Driver | High | Oncology |
| Growing number of clinical trials for new therapies enhances treatment options. | Driver | High | Biologic Therapies |
| Rising patient population needing targeted therapies creates significant market opportunities. | Opportunity | High | Hospitals |
| Government funding for cancer research initiatives opens new avenues for investment. | Opportunity | High | Research Hospitals |
| High cost of targeted therapies limits access for some patients. | Restraint | High | Biologic Therapies |
| Regulatory hurdles can delay the introduction of new therapies into the market. | Restraint | Medium | RNA-Based Therapies |
| Buyers face challenges in navigating complex approval processes for new therapies. | Challenge | High | Specialty Clinics |
| Suppliers struggle with fluctuating demand due to varying treatment protocols. | Challenge | Medium | Biotech Companies |
Evaluation of Drivers in China Targeted Therapy Market (2026–2032)
The main growth drivers and the segments they affect most are set out below.
| Drivers | Primary Segment Affected | Why It Matters (Evidence) |
| Rising cancer rates in urban areas drive demand for targeted therapies. | Oncology | In 2022, China's population diagnosed with cancer reached 4.6 million, increasing the need for effective treatments. |
| The increasing number of clinical trials expands treatment options for patients. | Biologic Therapies | In 2022, over 1,000 clinical trials for targeted therapies were conducted in China, broadening available therapies. |
| Government initiatives improve access to targeted therapies for patients. | Hospitals | The 2021 program by the National Health Commission aims to enhance access to targeted therapies for 1 million patients. |
| Growing investment in cancer research supports the development of new therapies. | Research Hospitals | In 2023, 500 million RMB was allocated for cancer research initiatives, boosting innovation in targeted therapies. |
| The rise in patient populations needing targeted therapies increases market demand. | Specialty Clinics | The average patient population receiving targeted therapy in major hospitals is approximately 50,000 annually. |
Market growth in China for Targeted Therapy is driven by rising cancer rates, an increase in clinical trials, and supportive government initiatives. In 2022, 4.6 million individuals in China were diagnosed with cancer, heightening the demand for effective treatments. More than 1,000 clinical trials for targeted therapies were conducted in 2022, broadening the range of available options. The National Health Commission's 2021 programme aimed to improve access for 1 million patients, further propelling demand. In 2023, the government allocated 500 million RMB for cancer research initiatives, promoting advancements in targeted therapies.
Evaluation of Restraints in China Targeted Therapy Market
The following restraints limit how fast demand can grow.
| Market Restraint | Primary Segment Affected | Why It Matters (Evidence) |
| High cost of targeted therapies limits access for some patients. | Biologic Therapies | The average cost of targeted therapy per patient in China is around 100,000 RMB per year, restricting affordability. |
| Regulatory hurdles can delay the introduction of new therapies into the market. | RNA-Based Therapies | Approval times can be prolonged due to the strict regulations enforced by the National Medical Products Administration. |
| Limited awareness among healthcare providers affects therapy adoption rates. | Specialty Clinics | Clinical guidelines for targeted therapy are updated annually, but not all providers stay informed, affecting treatment uptake. |
| Supply chain disruptions can impact the availability of targeted therapies. | Oncology | Ongoing reviews of pricing policies by the National Development and Reform Commission create uncertainty in supply chains. |
| Complexity in treatment protocols can hinder effective therapy implementation. | Biotech Companies | Navigating the integration of new therapies into existing treatment frameworks poses challenges for buyers. |
China Targeted Therapy Market Challenges
In China, buyers and suppliers in the targeted therapy market encounter rising costs, with the average treatment costing approximately 100,000 RMB per patient each year. Regulatory challenges arise as the National Medical Products Administration enforces strict guidelines, causing delays for distributors that hinder timely access to new therapies. Producers face skills shortages in advanced biotechnological processes, limiting their ability to innovate and impacting patient treatment options. Increased competition from both domestic and international players intensifies pricing pressures, compelling suppliers to lower margins, which may affect quality for buyers.
Trends in the China Targeted Therapy Market
The trends below show where the China Targeted Therapy Market is heading.
- Shift from Traditional to Targeted Therapies: Since 2021, there has been a marked shift towards targeted therapies in oncology, driven by the National Cancer Control Plan. This initiative aims to improve access for 1 million patients, reflecting a growing preference for precision medicine.
- Emergence of RNA-Based Therapies: In 2023, RNA-based therapies are gaining traction as a promising treatment option for genetic disorders. With a projected CAGR of 8.8%, this segment is becoming increasingly relevant in precision medicine.
- Focus on Biologic Therapies: Starting in 2022, biologic therapies have become a focal point in oncology due to their specificity and effectiveness. With targeted therapies accounting for 30% of oncology treatments, hospitals are increasingly adopting these therapies.
- Investment in Cancer Research: In 2023, the government allocated 500 million RMB for cancer research initiatives, underscoring a substantial commitment to targeted therapies. This funding is expected to drive innovation and expand treatment options for patients.
Investment Opportunities in the China Targeted Therapy Market
Several openings in the China Targeted Therapy Market merit attention from investors.
- Rising Demand for Targeted Therapies: With 4.6 million cancer diagnoses in 2022, there is a pressing need for targeted therapies. Hospitals are prime buyers, and partnerships with local firms could facilitate market entry.
- Government Funding for Research Initiatives: In 2023, the government allocated 500 million RMB for cancer research, creating opportunities for investment in new therapies. Collaborating with research hospitals can improve market presence.
- Expanding Patient Population: The average patient population receiving targeted therapy in major hospitals is around 50,000 annually, indicating a growing market. Establishing joint ventures with local healthcare providers can help meet this demand.
- Increasing Clinical Trials: With over 1,000 clinical trials for targeted therapies in 2022, the market is ripe for new entrants. Engaging with research institutions can provide valuable insights and facilitate product development.
Government Initiatives in the China Targeted Therapy Market
The National Health Commission's 'National Cancer Control Plan (2021-2025)' aims to improve access to targeted therapies for 1 million patients. This initiative ensures that more patients can receive effective treatments, thereby expanding the market for targeted therapies. The plan includes provisions for enhancing infrastructure and resources in healthcare facilities to support therapy implementation.
The Ministry of Science and Technology's '14th Five-Year Plan for Health' emphasises the development of targeted therapies, focusing on innovative drug research. This plan allocates funding to support research initiatives and the development of new therapies, ensuring that producers can innovate and meet market needs.
Future Insight of the China Targeted Therapy Market
The targeted therapy market in China is set to undergo notable changes by 2032, supported by several key developments. The National Health Commission's initiative to improve access to targeted therapies will enhance availability, especially in rural regions. A rise in clinical trials, with over 1,000 expected annually, will drive research and innovation. The Ministry of Science and Technology's commitment to advancing drug development will enable the introduction of new therapies, providing buyers and suppliers with a broader range of treatment options.
Market Segmentation Analysis
The report offers a comprehensive study of the following market segments and their leading categories in the market.
By Therapy Type – Biologic Therapies Dominated, RNA-Based Therapies Expected to Grow Fastest
According to Sumit Sagar, AM at 6Wresearch, Biologic Therapies took a 35% share of therapy type in 2025, more than any other category. Biologic therapies hold the largest share in the China targeted therapy market due to their precise effectiveness in treating various cancers. Their widespread use is evidenced by the substantial number of over 1,000 clinical trials currently underway in the country. The quickest growth will come from RNA-Based Therapies, forecast to expand at a CAGR of 8.3% between 2026 and 2032. RNA-based therapies are experiencing rapid growth as they become integral to precision medicine, particularly for addressing genetic disorders. The government's allocation of 500 million RMB for cancer research initiatives is a key factor driving this upward trend. Suppliers should focus on enhancing their biologic therapy offerings while also investing in RNA-based innovations to seize opportunities in the expanding market.
By Disease Indication – Oncology Dominated, Genetic Disorders Expected to Grow Fastest
Oncology held a 40% share of the China Targeted Therapy Market by disease indication in 2025. Oncology is the leading segment in the targeted therapy market, representing a significant share as it is the primary focus for these therapies. The diagnosis of 4.6 million cancer cases in 2022 highlights the robust demand for oncology-targeted treatments. Genetic Disorders are set to record the highest CAGR in this split, 8.2% over 2026–2032. Genetic disorders are the fastest-growing segment for targeted therapies, although their current applications are still developing. As research progresses, the potential for targeted therapies in this area is expected to expand significantly. Buyers should prepare for the introduction of new targeted therapies for genetic disorders, which may offer additional treatment options in the near future.
By Delivery Mode – Injection/IV Dominated, Nucleic Acid Delivery Expected to Grow Fastest
In 2025, Injection/IV led the delivery mode split with a 52% share. Injection/IV is the predominant delivery mode for targeted therapies, serving as the standard method for administering biologic therapies in clinical environments. This approach is vital for ensuring the effectiveness of treatments delivered to patients. Nucleic Acid Delivery is projected to grow fastest, at a CAGR of 8.8% during 2026–2032. Nucleic acid delivery is rapidly becoming essential, especially for RNA-based therapies that rely on this method for effective treatment. The growing emphasis on RNA-based therapies in clinical trials is likely to further fuel this delivery mode's growth. Suppliers must invest in advanced delivery technologies, particularly nucleic acid delivery systems, to remain competitive in the targeted therapy market.
By End User – Hospitals Dominated, Specialty Clinics Expected to Grow Fastest
The largest end user category in 2025 was Hospitals, with a 49% share of total revenue. Hospitals are the dominant end-user segment for targeted therapies, serving as the main providers of patient treatment in oncology. With approximately 50,000 patients receiving targeted therapy annually, hospitals play a crucial role in this market. Over 2026–2032, Specialty Clinics are expected to post the fastest growth, at a CAGR of 8.7%. Specialty clinics are emerging as the fastest-growing end-user segment, concentrating on specific diseases that require targeted therapies. Their focused approach to treatment is increasingly vital as demand for personalised care continues to rise. Suppliers should consider forming partnerships with specialty clinics to effectively address the growing demand for targeted therapies and ensure their products align with specific patient needs.
Key Attractiveness of the Report
- 10 Years of Market Numbers
- Historical Data Starting from 2022 to 2025
- Base Year 2025
- Forecast Data until 2032
- Key Performance Indicators Impacting the Market
- Major Upcoming Developments and Projects
Key Highlights of the Report:
- China Targeted Therapy Market Outlook
- Market Size of China Targeted Therapy Market, 2025
- Forecast of China Targeted Therapy Market, 2032
- Historical Data and Forecast of China Targeted Therapy Revenues & Volume for the Period 2022 - 2032F
- China Targeted Therapy Market Trend Evolution
- China Targeted Therapy Market Drivers and Challenges
- China Targeted Therapy Price Trends
- China Targeted Therapy Porter's Five Forces
- China Targeted Therapy Industry Life Cycle
- Historical Data and Forecast of China Targeted Therapy Market Revenues & Volume By Therapy Type for the Period 2022 - 2032F
- Historical Data and Forecast of China Targeted Therapy Market Revenues & Volume By Small Molecule Drugs for the Period 2022 - 2032F
- Historical Data and Forecast of China Targeted Therapy Market Revenues & Volume By Biologic Therapies for the Period 2022 - 2032F
- Historical Data and Forecast of China Targeted Therapy Market Revenues & Volume By RNA-Based Therapies for the Period 2022 - 2032F
- Historical Data and Forecast of China Targeted Therapy Market Revenues & Volume By Peptide Therapies for the Period 2022 - 2032F
- Historical Data and Forecast of China Targeted Therapy Market Revenues & Volume By Disease Indication for the Period 2022 - 2032F
- Historical Data and Forecast of China Targeted Therapy Market Revenues & Volume By Oncology for the Period 2022 - 2032F
- Historical Data and Forecast of China Targeted Therapy Market Revenues & Volume By Autoimmune Diseases for the Period 2022 - 2032F
- Historical Data and Forecast of China Targeted Therapy Market Revenues & Volume By Genetic Disorders for the Period 2022 - 2032F
- Historical Data and Forecast of China Targeted Therapy Market Revenues & Volume By Hormonal Disorders for the Period 2022 - 2032F
- Historical Data and Forecast of China Targeted Therapy Market Revenues & Volume By Delivery Mode for the Period 2022 - 2032F
- Historical Data and Forecast of China Targeted Therapy Market Revenues & Volume By Oral for the Period 2022 - 2032F
- Historical Data and Forecast of China Targeted Therapy Market Revenues & Volume By Injection/IV for the Period 2022 - 2032F
- Historical Data and Forecast of China Targeted Therapy Market Revenues & Volume By Nucleic Acid Delivery for the Period 2022 - 2032F
- Historical Data and Forecast of China Targeted Therapy Market Revenues & Volume By Nasal/Sublingual for the Period 2022 - 2032F
- Historical Data and Forecast of China Targeted Therapy Market Revenues & Volume By End User for the Period 2022 - 2032F
- Historical Data and Forecast of China Targeted Therapy Market Revenues & Volume By Hospitals for the Period 2022 - 2032F
- Historical Data and Forecast of China Targeted Therapy Market Revenues & Volume By Specialty Clinics for the Period 2022 - 2032F
- Historical Data and Forecast of China Targeted Therapy Market Revenues & Volume By Research Hospitals for the Period 2022 - 2032F
- Historical Data and Forecast of China Targeted Therapy Market Revenues & Volume By Biotech Companies for the Period 2022 - 2032F
- China Targeted Therapy Import Export Trade Statistics
- Market Opportunity Assessment By Therapy Type
- Market Opportunity Assessment By Disease Indication
- Market Opportunity Assessment By Delivery Mode
- Market Opportunity Assessment By End User
- China Targeted Therapy Top Companies Market Share
- China Targeted Therapy Competitive Benchmarking By Technical and Operational Parameters
- China Targeted Therapy Company Profiles
- China Targeted Therapy Key Strategic Recommendations
Market Covered
This report examines the market across the segments below.
By Therapy Type
- Small Molecule Drugs
- Biologic Therapies
- RNA-Based Therapies
- Peptide Therapies
By Disease Indication
- Oncology
- Autoimmune Diseases
- Genetic Disorders
- Hormonal Disorders
By Delivery Mode
- Oral
- Injection/IV
- Nucleic Acid Delivery
- Nasal/Sublingual
By End User
- Hospitals
- Specialty Clinics
- Research Hospitals
- Biotech Companies
